A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

Completed · Phase 2

Conditions studied: Hepatocellular Carcinoma, Liver Cancer, HCC

In brief

This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.

Key facts

Study ID
NCT01387555
Run by
Jennerex Biotherapeutics
People needed
129
Starts
2011-10-08
Expected to finish
2013-10-01
Last updated by the study team
2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.